Hyundai Motor's Record Sales but Stock Plunge: Real Reason / Surging KOSDAQ, 'This Stock' to Watch in May | Director Lee Young-hoon

Summary

The video analyzes Hyundai Motor's earnings miss and the market's disappointment, discussing the overdone pullback and future catalysts from new cars and humanoid robots. The conversation shifts to the KOSDAQ market's thematic rotation and the biotech sector, where large caps like Alteogen are seen as bottoming. The guest advises focusing on stocks with strong fundamentals and catalysts, predicting KOSPI will be range-bound in May.

• Hyundai Motor's Q1 earnings beat revenue but missed on profit due to tariffs and won strength, leading to a sharp selloff.
• The guest sees the pullback as overdone given unchanged long-term fundamentals and upcoming H2 new car launches.
• Hyundai's future value from humanoid robots and autonomous driving remains a key differentiator, but the market still views it as legacy auto.
• The biotech sector has been weak due to licensing-out valuation uncertainty and large-cap volatility, but Alteogen and ABL Bio are showing signs of bottoming.
• Alteogen's validated platform and licensing deal provide downside protection at current levels.
• KOSDAQ trading is theme-driven; stocks with hot catalysts (AI, space, policy) rally regardless of earnings.
• Low PBR holding companies with potential catalysts (succession, data center) are worth monitoring.
• KOSPI is expected to be range-bound in May without a strong rally.